hearing loss prevention chemotherapy fennec

Fennec Pharmaceuticals Announces FDA Acceptance of New Drug Application Resubmission for PEDMARK

RESEARCH TRIANGLE PARK, NORTH CAROLINA — Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the resubmission of its New Drug Application (NDA) for PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month…

Read More
thyroid drug hearing loss tepezza

Increased Risk of Hearing Loss Found with New Thyroid Eye Disease Treatment

More patients than previously reported may experience hearing symptoms, such as hearing loss or muffled hearing, from a new treatment for thyroid eye disease, teprotumumab (Tepezza), according to a small study that was presented virtually at ENDO 2021, the Endocrine Society’s annual meeting. Teprotumumab, approved by the U.S. Food and Drug Administration in January 2020,…

Read More
sensorion sens-401 cisplatin

Sensorion Provides Update on Development of SENS-401 for the Prevention of Hearing Loss

MONTPELLIER, FRANCE — Sensorion, a pioneering clinical stage biotechnology company which specializes in the development of novel therapies to restore, treat and  prevent within the field of hearing loss disorders, announces it plans to initiate a proof-of-concept clinical trial of SENS-401 to treat cisplatin-induced ototoxicity (CIO) in the second half (H2) of 2021. The company…

Read More

Purifying Gentamicin Could Reduce Risk of Hearing Loss

A Stanford Medicine-led study has found that a subtype of popular antibiotic could pose a reduced hearing loss risk, but still be effective at fighting off bacterial infections. An article discussing the promising new research recently appeared on the Stanford Medicine website. Gentamicin is used in U.S. hospitals to treat a variety of bacterial infections, including…

Read More
db-020 fast tracked fda

Decibel Therapeutics Announces DB-020 Granted Fast Track Designation by the FDA

BOSTON, MASSACHUSSETTS – Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that their clinical product candidate, DB-020, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). DB-020 is an investigational therapy for the prevention of cisplatin-induced hearing loss,…

Read More
opioid hearing loss

New Study Links Opioid Use with Hearing Loss

A retrospective study by researchers at Rutgers University has found that opioid use, particularly in high doses, can cause “full or partial hearing loss”. The study, published in The Journal of Medical Toxicology, reviewed records from the New Jersey Poison Control Center, based at Rutgers New Jersey Medical School, from 1999 to 2018 to determine the association between opioid…

Read More
chemo hearing loss tinnitus outcomes

Symptoms of Hearing Loss and Tinnitus May Indicate Poor Outcomes in Cancer Survivors

Development of chemotherapy-induced neuropathy (CIN), hearing loss, and/or tinnitus, in cancer survivors may be predictive of increased risk of severe symptom burdens and reduced quality of life (QoL), according to a study published in the European Journal of Oncology Nursing. All three conditions, CIN, hearing loss and tinnitus significantly detracts from patient QoL in numerous…

Read More
gasoline hearing loss lead

Reduction in Hearing Loss Prevalence Due to Phasing Out of Leaded Gasoline, Says One Researcher

Earlier this year, researchers reported in JAMA-Otolaryngology that the overall prevalence of hearing loss in the U.S. continues to decline among adults aged 20 to 69 years, even though adult hearing loss does continue to be linked with increasing age, noise exposure, educational level, ethnicity and gender. Specifically, in their March 2017 article, Hoffman and…

Read More
cystic fibrosis hearing loss tinnitus

Foundation Awards Sound Pharmaceuticals $1.6 Million for Prevention and Treatment of Antibiotic-Induced Hearing Loss

SEATTLE, WASHINGTON — Sound Pharmaceuticals, a Seattle-based biotech firm, announced this week that it has been awarded up to $1.6M from Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), a non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation. The CFFT award will support the initial testing of SPI-1005 in people with cystic fibrosis (CF)…

Read More
hearing loss cancer chemo

Study: Sodium Thiosulfate Treatment Significantly Reduces Chemotherapy-Induced Hearing Loss in Children

LOS ANGELES, CALIFORNIA — According to a new study, investigators at the Children’s Hospital Los Angeles and 37 other Children’s Oncology Group hospitals in the U.S. and Canada have found that sodium thiosulfate helps prevent cisplatin-induced hearing loss in children with cancer. Results of the randomized, controlled, phase 3 study, were published in this month’s…

Read More